Athens, 06/06/2021: . TIKUN Europe, the largest pharmaceutical company in the medical cannabis industry in Europe, has received a license to start the operations on its factory. The production process of the final medical cannabis products is expected in the near future.
TIKUN Europe’s factory is located in a privately owned area of 56,000 sq. m. in Corinth and is an investment of more than 30 million euros. The production facility is fully vertically integrated, having a R&D department and high-tech equipment. Tikun Europe’s factory has three distinct units: the greenhouse cultivation area, the post-harvest processing area, and the area designated for the production and packaging of finished medical cannabis products.
Also, TIKUN Europe’s factory, complies with the GACP / EU-GMP standards of the European Union and the domestic legislation for the cultivation and processing of medical cannabis, while its operation will be carried out with absolute responsibility and respect for the environment and the local community.
The new production unit was visited by the Minister of Development and Investments, Adonis Georgiadis, on Friday, June 3rd. The Minister's visit took place at a pivotal/crucial moment for the Company, following the legislation on medical cannabis and his first tour of the factory that had taken place 2 years ago. The Minister confirmed that the Government's commitment to investments has been implemented, with the plant launching the production process starting July.
The Nikos Beis CEO of TIKUN TIKUN OLAM Europe said: "It was a great pleasure to welcome the operating license of our production unit, the construction of which was recently completed. The operation of the plant will start very soon, bringing us one step closer to the realization of our vision: to meet the ever-increasing demand of Greece and Europe for high quality medical cannabis products. Our factory is the largest pharmaceutical company in the specific industry in Europe and exploits the potential of our country to play a leading role in the global market for medical cannabis."
TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.
About TIKUN Europe
TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.
With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.
TIKUN Europe’s activity is fully aligned with the GACP/GMP principles and the provisions of Greek legislation for the cultivation and processing of medical cannabis, ensuring high product quality and safety.
The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD).
At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.
V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / 6936775484 - Email email@example.com firstname.lastname@example.org